AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35212470
Drug: Antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment (ART)
Trial: 32271899
Drug: Tisagenlecleucel infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisagenlecleucel infusion
Trial: 36209432
Drug: Decongestive lymphatic
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestive lymphatic therapy (DLT)
Trial: 32581513
Drug: Agalsidase alfa
RxNorm normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Agalsidase alfa enzyme replacement therapy (ERT)
Trial: 37646208
Drug: Angiotensin-Converting Enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-Converting Enzyme Inhibitors (ACEIs)
Trial: 38670599
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (specific treatment not mentioned)
Trial: 34006291
Drug: Matched therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched therapy
Trial: 35238467
Drug: Unmatched therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmatched therapy
Trial: 37924481
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVT-AFL) treatment
Trial: 37326854
Drug: Belimumab 10
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab 10 mg/kg IV
Trial: 32000408
Drug: Instrumental activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instrumental activities of daily living scale (IADL)
Trial: 32000590
Drug: Anticoagulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation treatment for atrial fibrillation after intracerebral hemorrhage
Trial: 32000819
Drug: Multisession radiosurgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisession radiosurgery delivering 25 Gy in 5 daily fractions
Trial: 32003099
Drug: Second-line insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second-line insulin secretagogues (IS) or insulin
Trial: 32003099
Drug: No IS
RxNorm normalized name: Alpha amino isobutyric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No IS and insulin
Trial: 32003749
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted cognitive behavioral internet-delivered treatment
Trial: 32004245
Drug: Multipoint pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multipoint pacing (MPP) activated ON at implant for patients with RV-to-LV delay less than 80 ms
Trial: 32005112
Drug: Standardized questionnaires
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized questionnaires administered at three time points (t1, t2, t3)
Trial: 32005333
Drug: Smartphone-delivered individual
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-delivered individual cognitive-behavioral therapy (CBT) for BDD
Trial: 32011909
Drug: SPT-Intense (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPT-Intense (3 hourly sessions per day/3 days per week)
Trial: 32012106
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments for UTUC (specific treatments not detailed)
Trial: 32012114
Drug: Nurse-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-delivered cognitive behavioral therapy (CBT-AD) for adherence and depression; 8 sessions.
Trial: 32012114
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (control group).
Trial: 32012214
Drug: Loncastuximab tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loncastuximab tesirine at 15 to 150 μg/kg IV once every 3 weeks (Q3W) or 50 μg/kg IV weekly.
Trial: 32015419
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of tolvaptan and pioglitazone
Trial: 32016127
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) for 3 years
Trial: 32016427
Drug: AMH in
RxNorm normalized name: Sodium Fluoride 0.007 mg in 35 mL ORAL SPRAY [AMHEALER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMH in early postmenarchal girls (5.2 ± 0.3 ng/mL)
Trial: 32016643
Drug: 24-h urinary
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-h urinary excretion measurement
Trial: 32016643
Drug: Correlation analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation analysis between self-reported intake and urinary excretion
Trial: 32017341
Drug: Ulimorelin 600-1200
RxNorm normalized name: Ulimorelin
DrugBank: Ulimorelin (DB12128)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulimorelin 600-1200 µg/kg
Trial: 32017341
Drug: Ulimorelin 150-600
RxNorm normalized name: Ulimorelin
DrugBank: Ulimorelin (DB12128)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulimorelin 150-600 µg/kg
Trial: 32017433
Drug: Individualized appropriate
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized appropriate medical therapy (AMT)
Trial: 32019278
Drug: Anthracycline-Taxane-Based Neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline-Taxane-Based Neoadjuvant Chemotherapy
Trial: 32019278
Drug: Carboplatin-containing treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin-containing treatment
Trial: 37789300
Drug: 38% Silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38% Silver Diamine Fluoride (SDF) solution
Trial: 32020437
Drug: RO6839921 (inactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO6839921 (inactive pegylated prodrug of idasanutlin) administered at doses of 120-300 mg, with maximum tolerated dose (MTD) identified as 200 mg.
Trial: 32020437
Drug: RO6839921 (inactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO6839921 (inactive pegylated prodrug of idasanutlin) administered at doses of 120-300 mg.
Trial: 32021066
Drug: Baerveldt-350 glaucoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baerveldt-350 glaucoma implant (BGI)
Trial: 32021066
Drug: Ahmed glaucoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ahmed glaucoma implant (AGV-S2 and FP7 models)
Trial: 32021387
Drug: Low-dose manual
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose manual acupuncture (MAL)
Trial: 32021387
Drug: High-dose manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose manual acupuncture (MAH)
Trial: 32021913
Drug: Nitroglycerin (Transiderm-Nitro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (Transiderm-Nitro 5 patch) during radiotherapy
Trial: 32022437
Drug: Videolaryngoscopy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videolaryngoscopy and combination techniques for intubation
Trial: 32022692
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy program (Breathe)
Trial: 32024786
Drug: Multicomponent menstrual
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent menstrual health management (MHM) intervention including teacher training, menstrual kit use, pain management, drama skit, provision of analgesics, and improvements to school facilities.
Trial: 32025741
Drug: IncobotulinumtoxinA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA treatment (shoulder injections)
Trial: 32025741
Drug: No shoulder
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No shoulder treatment (control group)
Trial: 32026243
Drug: Pirfenidone, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone, administered in three divided doses daily, median dose 2400 mg/day, exposure duration median 3.0 years.
Trial: 32026347
Drug: Pirfenidone, mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone, mean (SD) daily dose 2058.7 (399.2) mg, mean (SD) exposure 22.8 (9.6) weeks
Trial: 32026407
Drug: Vismodegib 150
RxNorm normalized name: vismodegib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib 150 mg plus pirfenidone 2403 mg/day once daily
Trial: 32026411
Drug: Ambroxol 20
RxNorm normalized name: ambroxol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol 20 mg hard-boiled lozenges
Trial: 32026411
Drug: Placebo hard-boiled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo hard-boiled lozenges
Trial: 32026814
Drug: Therapy interventions
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy interventions
Trial: 32027846
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg plus savolitinib 600 mg daily (part B)
Trial: 32027846
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg plus savolitinib 300 mg daily (part D)
Trial: 32028209
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxicity
Trial: 32028985
Drug: 3 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks of targeted postsurgical systemic antibiotic therapy for implant-free SIs
Trial: 32028985
Drug: 6 weeks
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weeks of targeted postsurgical systemic antibiotic therapy for implant-related SIs
Trial: 32028985
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events of antibiotic therapy
Trial: 32028991
Drug: HepaStem (liver-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HepaStem (liver-derived mesenchymal stem cells) with anticoagulants (heparin and bivalirudin)
Trial: 32028998
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study
Trial: 32030422
Drug: Sodium zirconium
RxNorm normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium zirconium cyclosilicate (SZC) 10 g three times daily for 24-72 hours followed by 5 g once daily for ≤12 months
Trial: 32030422
Drug: Sodium zirconium
RxNorm normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium zirconium cyclosilicate (SZC) 5 g once daily during maintenance phase (MP)
Trial: 32030595
Drug: Antipsychotic Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic Medication Management Fidelity Scale
Trial: 32031690
Drug: Vasomodulator Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasomodulator Therapy
Trial: 32031693
Drug: Lenvatinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib at a dose of 24 mg/day
Trial: 32032174
Drug: Anidulafungin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anidulafungin (3 mg/kg on day 1, 1.5 mg/kg daily thereafter) for 5-35 days
Trial: 32032309
Drug: Booster vaccine
RxNorm normalized name: Moderna COVID-19 (6y+) Bivalent Booster Vaccine PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster vaccine against diphtheria
Trial: 32033600
Drug: 200 mcg
RxNorm normalized name: CrM 200 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg slow-release misoprostol vaginal insert
Trial: 32033600
Drug: 25 mcg
RxNorm normalized name: D3, 25 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mcg oral misoprostol tablets
Trial: 32034017
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy (GDMT) with beta-blockers and RAS inhibitors
Trial: 32034017
Drug: Beta-blockers only
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers only
Trial: 32034017
Drug: RAS inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS inhibitors only
Trial: 32034416
Drug: Equine-assisted therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equine-assisted therapy (EAT) for PTSD, administered in an eight-session group protocol.
Trial: 32034630
Drug: Adavosertib 175
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib 175 mg bid for 2.5 days with carboplatin alone or paclitaxel plus carboplatin
Trial: 32034630
Drug: Adavosertib 225
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib 225 mg bid in combination with paclitaxel plus carboplatin
Trial: 32034630
Drug: Adavosertib 175
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib 175 mg bid for 2.5 days
Trial: 32035752
Drug: Intravenous pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pulse and primed constant infusion of multiple stable tracers of amino acids
Trial: 32036486
Drug: Platelet responses
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet responses to other agonists, CD62P platelet surface expression, and PMA levels
Trial: 32036499
Drug: PPI augmentation
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI augmentation during SBT
Trial: 32037403
Drug: Tivozanib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib (1 mg per os once daily, 21 days on-7 days off)
Trial: 32038751
Drug: Lidose-isotretinoin administered
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidose-isotretinoin administered without food
Trial: 32040549
Drug: JNJ-64407564 (GPRC5DxCD3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64407564 (GPRC5DxCD3 bispecific antibody)
Trial: 32040562
Drug: Pramipexole (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (0.5 mg/day titrated to a maximum daily dose of 2.5 mg)
Trial: 32040562
Drug: Baseline D2/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline D2/3 receptor availability
Trial: 32040573
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum miR-622 expression prior to first-line platinum-based chemotherapy
Trial: 32041862
Drug: Lymphodepleting chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepleting chemotherapy (intravenous fludarabine and cyclophosphamide)
Trial: 32042283
Drug: C1-INH (SC)
RxNorm normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1-INH (SC) 40 IU/kg or 60 IU/kg twice weekly for 52 to 140 weeks
Trial: 32043771
Drug: De novo
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De novo patients receiving first-line regimens containing chemotherapy (89.7%), trastuzumab (95.7%), and pertuzumab (77.8%)
Trial: 32043771
Drug: Recurrent patients
RxNorm normalized name: Acacia decurrens extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recurrent patients receiving first-line regimens containing chemotherapy (80.0%), trastuzumab (85.9%), and pertuzumab (68.6%)
Trial: 32043777
Drug: Ruxolitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (5 mg twice daily, with dose increases to 10 mg twice daily permitted after 3 days in the absence of toxicity)
Trial: 32043778
Drug: HyperAcute Renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HyperAcute Renal (HAR) immunotherapy
Trial: 32043778
Drug: HyperAcute Renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HyperAcute Renal (HAR) immunotherapy (low-dose)
Trial: 32043778
Drug: HyperAcute Renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HyperAcute Renal (HAR) immunotherapy (high-dose)
Trial: 32044400
Drug: Remestemcel-L (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remestemcel-L (human mesenchymal stromal cells) administered as 8 biweekly intravenous infusions.
Trial: 32045583
Drug: Fixed-dose enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose enoxaparin 40 mg daily
Trial: 32045583
Drug: Weight-tiered enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-tiered enoxaparin (30 mg daily for <70 kg, 40 mg daily for 70-89.9 kg, 50 mg daily for ≥90 kg)
Trial: 32046348
Drug: CC genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC genotype of the rs699947 variant
Trial: 32046725
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation (MBP) + Oral antibiotics (OA)
Trial: 32047645
Drug: High-dose cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cholecalciferol supplementation (20,400 IU every other day)
Trial: 32047645
Drug: Low-dose cholecalciferol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cholecalciferol supplementation (400 IU every other day)
Trial: 32047896
Drug: Late acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late acute GVHD (L-aGVHD)
Trial: 32047896
Drug: Active L-aGVHD
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active L-aGVHD before day 114
Trial: 32047896
Drug: No cGVHD/L-aGVHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cGVHD/L-aGVHD
Trial: 32048179
Drug: Oral cannabidiol-rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabidiol-rich cannabis extracts
Trial: 32048179
Drug: Co-administration with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration with zonisamide
Trial: 32048179
Drug: Co-administration with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration with levetiracetam
Trial: 32048753
Drug: N-of-1 trials
RxNorm normalized name: (Alginate)n+1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-of-1 trials with effective treatment for at least one month
Trial: 32048808
Drug: Family-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based treatment (FBT) for childhood obesity, duration: 6 months
Trial: 32048808
Drug: Family-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based treatment (FBT) for childhood obesity, sessions 10 to 20
Trial: 32048889
Drug: Combined DTPa-IPV/Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose
Trial: 32049318
Drug: peg-IFN treatment
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peg-IFN treatment
Trial: 32050447
Drug: Aerosolised plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolised plus intravenous vancomycin; dosage and duration not specified
Trial: 32050447
Drug: Control group;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group; treatment not specified
Trial: 32052264
Drug: Mirogabalin 5
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 5 mg BID
Trial: 32052264
Drug: Mirogabalin 10
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 10 mg BID
Trial: 32052315
Drug: HPR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPR and β-amyloid > 51 mg/dl
Trial: 32052315
Drug: HPR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPR and MOTS-c < 167 ng/ml
Trial: 32053203
Drug: Analytical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analytical Treatment Interruption (ATI)
Trial: 32053612
Drug: Citicoline 1000
RxNorm normalized name: citicoline 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline 1000 mg once daily for 12 months
Trial: 32053771
Drug: Celyvir (autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celyvir (autologous MSCs carrying oncolytic adenovirus), administered intravenously, 2 × 10^9 cells weekly for 6 weeks